![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
MAPPP 12+
Island Peer Review Organization, Inc
Designed for iPad
-
- Free
Screenshots
Description
Despite the considerable efficacy of antithrombotics and the increased number of oral anticoagulants now available, preventable bleeding and thrombotic events are still unacceptably common. While recently marketed agents require less laboratory monitoring, problems with the clinical management of anticoagulated patients persist, particularly in the peri-procedural period.
Surgery and invasive medical interventions increase the risk of bleeding, while withholding anticoagulants increases the risk of thrombosis due to the underlying condition(s) for which anticoagulation was originally prescribed. The clinical team must therefore balance these competing risks and make educated decisions regarding the decision to interrupt oral anticoagulation for a medical procedure and, if interrupted, whether to "bridge" anticoagulation with injectable anticoagulants, such as low molecular weight heparin (LMWH) in warfarin treated patients.
This guide is intended to:
-Assist clinicians in the simultaneous evaluation of procedure-related bleeding risk and underlying risk of thrombosis
-Guide decisions regarding the interruption of anticoagulation and the use of anticoagulant "bridging"
-Provide detailed guidance for drug dosing and laboratory monitoring in the peri-procedural period
-Encourage clear communication between clinicians involved in prescribing anticoagulants and performing invasive procedures
This material was created by the multidisciplinary members of the Peri-Procedural Task Force of the New York State Anticoagulation Coalition and IPRO, the Medicare Quality Improvement Organization for New York State, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents do not necessarily reflect CMS policy. 10SOW-NY-AIM-7.3-14-01
What’s New
Version 1.2.71
-minor fixes
App Privacy
The developer, Island Peer Review Organization, Inc, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer's privacy policy.
Data Used to Track You
The following data may be used to track you across apps and websites owned by other companies:
- Location
- Identifiers
- Usage Data
Data Not Linked to You
The following data may be collected but it is not linked to your identity:
- Location
- Identifiers
- Usage Data
Privacy practices may vary, for example, based on the features you use or your age. Learn More
Information
- Seller
- Island Peer Review Organization, Inc
- Size
- 62.7 MB
- Category
- Medical
- Compatibility
-
- iPhone
- Requires iOS 11.0 or later.
- iPad
- Requires iPadOS 11.0 or later.
- iPod touch
- Requires iOS 11.0 or later.
- Mac
- Requires macOS 11.0 or later and a Mac with Apple M1 chip or later.
- Apple Vision
- Requires visionOS 1.0 or later.
- Languages
-
English
- Age Rating
- 12+ Infrequent/Mild Medical/Treatment Information
- Copyright
- © Island Peer Review Organization, Inc
- Price
- Free